Abstract
Three years after development of the entire class of nerve growth factor (NGF) inhibitors was put on clinical hold by the US FDA over serious safety concerns related to joint destruction, Pfizer has decided to continue Phase III development of its anti-NGF antibody tanezumab in collaboration with Eli Lilly as part of a deal potentially worth up to US$1.8 B. In March 2012, an FDA advisory committee agreed that NGF inhibitors could be studied in certain patient populations. Pfizer hopes to resume studies of the drug in osteoarthritis, chronic low back pain and cancer pain after submitting nonclinical data to the FDA in the first half of 2014.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
